Marcus Borenäs

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of <i>ALK</i> mutation

Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai et al. · The EMBO Journal · 2021 · 62 citations · Full text

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Muhammad Wasi Alam, Marcus Borenäs, Dan E. Lind et al. · Frontiers in Oncology · 2019 · 37 citations · Full text

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

Diana Cervantes-Madrid, Joanna Szydzik, Dan E. Lind et al. · Scientific Reports · 2019 · 27 citations · Full text

Analysis of <i>ALK</i>, <i>MYCN</i>, and the ALK ligand <i>ALKAL2</i> (<i>FAM150B/AUGα</i>) in neuroblastoma patient samples with chromosome arm 2p rearrangements

Niloufar Javanmardi, Susanne Fransson, Anna Djos et al. · Genes Chromosomes and Cancer · 2019 · 26 citations

Medicine, Receptor Tyrosine Kinase, Chromosome Arm 2P +14

ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

Marcus Borenäs, Ganesh Umapathy, Dan E. Lind et al. · Proceedings of the National Academy of Sciences · 2023 · 21 citations · Full text

Cell Death, Cancer Biology, Tumor Biology +16